NCT05316181View on ClinicalTrials.gov

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

PHASE3RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2029

Conditions
Epithelial Ovarian CancerPlatinum ResistantRecurrent OvarianHIPECMitomycinCytoreductive Surgery
Interventions
PROCEDURE

HIPEC

HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.

Trial Locations (3)

10408

RECRUITING

Myong Cheol Lim, Goyang-si

Unknown

RECRUITING

Ewha Womans University Mokdong Hospital, Seoul

RECRUITING

Korea University Anam hospital, Seoul

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV